Activation of HLA-G expression by 5-aza-2′- deoxycytidine in malignant hematopoetic cells isolated from leukemia patients

Neoplasma

Volumn 56, Issue 6, 2009, Pages 514-520

  Polakova, K ^a   Bandzuchova, E ^b   Sabty, F A ^c   Mistrik, M ^c   Demitrovicova, L ^d   Russ, G ^e  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^c Physics and Informatics   (Slovakia)

^d CANCER RESEARCH INSTITUTE   (Slovakia)

^e INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

5 aza 2 Deoxycytidine; AML; B CLL; DNA demethylation; HLA G

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HLA G ANTIGEN; MESSENGER RNA; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA-G ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DEMETHYLATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MALE; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; DNA METHYLATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOTTING, WESTERN; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELL TRANSPLANTATION;

EID: 70449714004     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_06_514     Document Type: Article

References (39)

1. HIBY SE, KING A, SHARKEY A, et al. Molecular studies of trophoblast HLA-G: polymorphism, isoforms, imprinting and expression in preimplantation embryo.Tissue Antigens 1999; 53: 1-13. doi:10.1034/j.1399-0039.1999.530101.x
2. HUNT JS. Stranger in a strange land. Immunol Rev 2006; 213: 36-47. doi:10.1111/j.1600-065X.2006.00436.x
3. SELIGER B, ABKEN H, FERRONE S, et al. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003; 24: 82-7. doi:10.1016/S1471-4906(02)00039-X
4. ROUAS-FREISS N, MOREAU P, FERRONE S, et al. HLA-G proteins in cancer: Do they provide tumor cells with an escape mechanism? Cancer Res 2005; 65: 10139-44. doi:10.1158/0008-5472.CAN-05-0097
5. UROSEVIC M, DUMMER R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res 2008; 68: 627-30. doi:10.1158/0008-5472.CAN-07-2704
6. CAROSELLA ED, FAVIER B, ROUAS-FREISS N, et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111: 4862-70. doi:10.1182/blood-2007-12-127662
7. GOBIN SJ, BIESTA P, DE STEENWINKEL JE, et al. HLA-G transactivation by cAMP-response element-binding protein (CREB). An alternative transactivation pathway to the conserved major histocompatibility complex (MHC) class I regulatory routes. J Biol Chem 2002; 277: 39525-31. doi:10.1074/jbc.M112273200
8. SOLIER C, MALLET V, LENFANT F, et al. HLA-G unique promoter region: functional implications. Immunogenetics 2001; 53: 617-25. doi:10.1007/s00251- 001-0373-0
9. HOWCROFT TK, SINGER DS. Expression of nonclassical MHC class Ib genes: comparison of regulatory elements. Immunol Res 2003; 27: 1-30. doi:10.1385/IR:27:1:1
10. MOREAU P, MOUILLOT G, ROUSSEAU P, et al. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 2003; 100: 1191-96. doi:10.1073/pnas.0337539100
11. MOUILLOT G, MARCOU C, ROUSSEAU P, HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer 2005; 113: 928-36. doi:10.1002/ijc.20682
12. YAN WH, LIN AF, CHANG CC, FERRONE S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′- deoxycytidine. Cell Res 2005; 15: 523-31.
13. MENENDEZ L, WALKER LD, MATYUNINA LV, et al. Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol Cancer 2008; 7: 43-51. doi:10.1186/1476-4598-7-43
14. POLAKOVA K, BANDZUCHOVA E, KUBA D, et al. Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk Res 2009; 33: 518-24. doi:10.1016/j.leukres.2008.08.003
15. POLAKOVA K, BANDZUCHOVA E, TIRPAKOVA J, et al. Modulation of HLA-G expression. Neoplasma 2007; 54: 455-62.
16. IBRAHIM EC, MORANGE M, DAUSSET J, et al. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones 2000; 5: 207-18. doi:10.1379/1466-1268(2000) 005〈0207:HSAAIE〉2.0.CO;2
17. MOUILLOT G, MARCOU C, ZIDI I, et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007; 68: 277-85. doi:10.1016/j.humimm. 2006.10.016
18. RITEAU B, MENIER C, KHALIL-DAHER I, et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 2001; 13: 193-201. doi:10.1093/intimm/13.2.193
19. ROUAS-FREISS N, NAJI A, DURRBACH A, et al. Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. Transplantation 2007; 84: S21-5. doi:10.1097/01.tp.0000269117.32179.1c
20. MAKI G, HAYES GM, NAJI A, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22: 998-1006. doi:10.1038/leu.2008.15
21. MUND C, BRUECKNER B, LYKO F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 2006; 1: 7-13.
22. JABBOUR E, ISSA JP, GARCIA-MANERO G, et al. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008; 112: 2341-51. doi:10.1002/cncr.23463
23. SABA HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3: 807-17.
24. GARCIA-MANERO G, YANG AS, JAGASIA M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol 2007; 5: 1-9.
25. MUND C, HACKANSON B, STRESEMANN C, et al. Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005; 65: 7086-90. doi:10.1158/0008-5472. CAN-05-0695
26. AMIOT L, ONNO M, DRÉNOU B, et al. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum Immunol 1998; 59:524-8. doi:10.1016/S0198-8859(98)00041-X
27. NÜCKEL H, REBMANN V, DÜRIG J, et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105: 1694-8. doi:10.1182/blood-2004-08-3335
28. YAN WH, LIN A, CHEN BG, et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008; 12: 889-98. doi:10.1111/j.1582-4934.2008.00175.x
29. PEREZ-CHACON G, ROSADO S, REBOLLEDA N, et al. Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int J Lab Hematol 2009; 31: 327-37. doi:10.1111/j.1751-553X.2008.01030.x
30. MAKI G, HAYES GM, NAJI A, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22: 998-1006. doi:10.1038/leu.2008.15
31. SEBTI Y, LE FRIEC G, PANGAULT C, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003; 64:1093-101. doi:10.1016/j.humimm.2003.08.345
32. GROS F, SEBTI Y, DE GUIBERT S, et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 2006; 8: 223-30. doi:10.1593/neo.05703
33. GIANNOPOULOS K, SCHMITT M, KOWAL M, et al. The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). Leuk Res 2008; 32: 1815-9. doi:10.1016/j.leukres.2008.04.008
34. LELEU X, LE FRIEC G, FACON T, et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res 2005; 11: 7297-303. doi:10.1158/1078-0432.CCR-05- 0456
35. LE MAUX A, NOËL G, BIREBENT B, et al. Soluble human leukocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol 2008; 152: 50-6.
36. RACCA AL, VEAUTE CM, BAILAT AS, et al. Expression of HLA-G and MICA mRNA in renal allograft. Transpl Immunol 2009; 21: 10-2. doi:10.1016/j.trim.2009.01. 002
37. LILA N, CARPENTIER A, AMREIN C, et al. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000; 355: 2138. doi:10.1016/S0140-6736(00)02386- 2
38. CREPUT C, LE FRIEC G, BAHRI R, et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 2003; 64: 1033-8. doi:10.1016/j.humimm.2003.08.356
39. LILA N, AMREIN C, GUILLEMAIN R, et al. Soluble human leukocyte antigen-G: a new strategy for monitoring acute and chronic rejections after heart transplantation. J Heart Lung Transplant 2007; 26: 421-2. doi:10.1016/j.healun. 2007.01.001